Omega Therapeutics is delveoping an approach to use mRNA therapeutics as programmable epigenetic medicines by utilizing its OMEGA Epigenomic Programming platform. Co. designs and engineers its mRNA therapeutics, which are programmable and modular epigenetic medicines, called Omega Epigenomic Controllers (OECs) to target EpiZips for Precision Genomic Control. Co.'s pipeline consists of early-stage, preclinical programs that span oncology, multigenic diseases. Co. has conducted in vivo preclinical studies of its OECs in multiple disease models for various indications, including hepatocellular carcinoma, non-small cell lung cancer, and acute respiratory distress syndrome.